

1 Estimation of lean body mass by creatinine kinetics increases the prevalence of
2 muscle wasting in peritoneal dialysis patients compared to bioimpedance

3

4 MD, Suree Yoowannakul MD, Andrew Davenport FRCP

5

6

7 UCL Centre for Nephrology

8 Royal Free Hospital

9 University College London

10 Rowland Hill Street

11 London NW3 2PF

12 UK

13

14

15 Address for correspondence

16

17 Suree Yoowannakul

moo_yookul@hotmail.com

18 Andrew Davenport

andrewdavenport@nhs.net

19

20

21 contact andrewdavenport@nhs.net

22 UCL Centre for Nephrology, Royal Free Hospital, University College London

23 Medical School, Rowland Hill Street, London NW3 2PF

24 tel 44-2074726457 fax 44-2073178591

25

26

27

28 short title creatinine kinetics and bioimpedance

29

30

31 key words chronic kidney disease peritoneal dialysis muscle wasting

32

creatinine kinetics bioimpedance lean body mass

33

34

35 word count abstract 149

36 body 951

37 figures 1

38 Tables 1

39 references 10

40

41 Acknowledgements: Dr Suree Yoowannakul was awarded an International Society

42 of Nephrology training award.

43

44

45

46 Abstract

47

48 Dialysis patients are at increased risk for muscle wasting, and time efficient
49 screening tests are required for to allow for early detection. Creatinine kinetics
50 have been advocated to estimate lean body mass (LBM) in peritoneal dialysis
51 (PD) patients, and can be readily calculated in clinical practice from peritoneal
52 dialysate effluent and urine collections. Bioimpedance is increasingly available,
53 and we compared methods in 434 PD patients (55% men, 33.3% diabetics), mean
54 age 55.2±16.2 years. LBM was lower by creatinine kinetics (47.8±16.6 kg men,
55 37.8±11.2 kg women) vs bioimpedance (53.2±11.5 kg men, 39.2±7.2 kg women),
56 $p < 0.01$. The prevalence of muscle wasting was much greater using creatinine
57 kinetics (72.4% men, 52.4% women) vs bioimpedance (55.2% men, 37.3%), $p < 0.05$.
58 Estimates of LBM were much lower using creatinine kinetics compared to
59 bioimpedance. Studies reporting the prevalence of muscle loss in PD patients will
60 differ depending upon the method used to estimate muscle mass.

61

62 Introduction

63 Dialysis patients are at increased risk of muscle wasting, and muscle
64 wasting is associated with increased risk for mortality. Peritoneal dialysis (PD)
65 patients have additional protein losses in the spent dialysate. For routine clinical
66 practice simple screening tests are required to detect muscle wasting
67 (sarcopenia) at an early stage to allow for intervention. Several methods have
68 been advocated for assessing lean body mass in dialysis patients and creatinine
69 kinetics is one method supported by the Kidney Disease Outcome Quality

70 Initiative (KDOQI) clinical guidelines committee [1]. Creatinine kinetics have
71 been used to estimate lean body mass in PD patients [2]. Bioimpedance devices
72 are being increasingly used in clinical practice, and can be used to assess body
73 composition [3], and studies have reported that bioimpedance provides
74 equivalent results to dual-energy x-ray absorptiometry (DXA) in PD patients [4].
75 As the prevalence of muscle wasting varies considerably between studies in PD
76 patients, we wished to compare the estimations of lean body mass using
77 creatinine kinetics and bioimpedance to determine whether the method used
78 changed the reported prevalence of muscle wasting.

79

80 Materials and Methods

81 Creatinine kinetics were calculated from corresponding 24-hour spent
82 peritoneal dialysate effluents, 24-hour urine collections and serum samples,
83 using standard equations [5], when patients attended for routine testing of
84 peritoneal membrane function. Enzymatic methods were used to measure
85 creatinine to exclude interference from glucose [6]. Multifrequency segmental
86 bioimpedance was performed in a standardised manner after patients had voided
87 and peritoneal dialysate drained out (InBody700, Seoul, Korea) [7]. The
88 bioimpedance machine was regularly serviced and calibrated. Muscle wasting was
89 defined by age and gender matched reference data obtained from the National
90 Health and Nutritional Survey (NHANES) [8].

91 This retrospective audit complied with the UK National Health Service
92 (NHS) guidelines for clinical audit and service development.

93

94 Statistical analysis

95 Data is presented as mean \pm standard deviation, median (interquartile
96 range), or as percentage. Standard statistical tests were used to analyse data.
97 using Prism 7.0 (Graph Pad, San Diego, USA) and SPSS 24 (SPSS, University of
98 Chicago, Chicago, USA) and Analyse It 4.0 (Analyse-It, Leeds, UK). Statistical
99 significance was taken as $p < 0.05$.

100

101 Results

102 We compared lean body mass estimated by creatinine kinetics and
103 bioimpedance in 434 PD patients (table 1). Lean body mass estimated by
104 creatinine kinetics was lower for both men (47.8 ± 16.6 kg) and women (37.8 ± 11.2
105 kg) vs bioimpedance (53.2 ± 11.5 kg men, 39.2 ± 7.2 kg women), $p < 0.01$. The mean
106 bias on Bland Altman analysis showed creatinine kinetics under-estimating lean
107 body mass compared to bioimpedance by 3.8 kg (Figure 1), with mean bias less
108 for women 1.6 kg (95% limits of agreement -18.5 to 21.8 kg), and 5.5 kg (-22.5 to
109 33.5 kg). Using NHANES reference data, the prevalence of muscle wasting was
110 72.4% for men and 52.4% for women by creatinine kinetics vs 55.2% for men
111 and 37.3% for women using bioimpedance, $p < 0.05$. Dividing patients according to
112 ethnicity lean body mass was not statistically different (European: females 19.7
113 (14.0-27.9), males 21.3 (14.7-33.4); Asian: females 19.1 (17.0-29.8), males 21.4
114 (14.4-31.2); African Afro-Caribbean: females 19.8 (14.0-33.4), males 17.9 (12.9-
115 30.9) kg, respectively.

116

117 Discussion

118 Studies in dialysis patients have repeatedly reported that loss of muscle
119 mass is strongly associated with an increased risk in mortality. Once established
120 protein energy wasting is difficult to reverse, and as such simple screening tests
121 are required for every day clinical practice. The routine samples obtained when
122 PD patients attend for assessment of peritoneal membrane function allow
123 estimation of lean body mass by calculating the creatinine index [5], and this
124 method has been supported by the KDOQI committee [1]. A validation study of
125 creatinine index reported similar estimates of lean body mass to those obtained
126 with DXA in PD patients, although the number of patients studied was very small
127 [2]. Bioimpedance devices are now more readily available in clinical practice, with
128 estimates of body composition in both haemodialysis and PD patients reported
129 to correlate strongly with DXA measurements [4,9].

130 Studies reporting on the prevalence of loss of muscle mass (sarcopenia) in
131 dialysis patients have varied in results, and as such we wished to determine
132 whether some of this variance could be due to the method used to estimate
133 muscle mass. We found that creatinine kinetics under-estimated lean body mass
134 compared to that measured with bioimpedance, and the mean bias was greater
135 for men compared to women, as male dialysis patients typically have greater
136 muscle mass and are more physically active [10]. We had too few anuric patients
137 to determine whether potential differences in non-renal creatinine excretion
138 and metabolism resulted in in greater bias, compared to those with residual

139 renal function. We did not find differences between ethnic groups, but this may
140 have been due to analysis of small numbers and differences in patient
141 demographics. Similarly we did not observe a difference with peritoneal
142 transport status.

143 When we then compared estimates of muscle mass with recognized age and
144 gender matched reference data [7], we found that the prevalence of muscle loss
145 (sarcopenia) was significantly greater when using creatinine kinetics. When
146 calculating creatinine kinetics, although urinary and peritoneal creatinine can be
147 measured by routine laboratory methods, the higher glucose concentration in
148 the spent peritoneal dialysate effluent may interfere with standard Jaffe
149 creatinine assays. To overcome this potential error, we used enzymatic methods.

150 In the steady state, estimation of lean body mass and creatinine kinetics are
151 closely correlated in healthy subjects, however in dialysis patients greater
152 amounts of creatinine are secreted into the intestine, some of which is then
153 reabsorbed, and then a variable proportion is converted back to creatine [5]. As
154 such creatinine kinetics, potentially under-estimates lean body mass in patients
155 with chronic kidney disease, and we found that the creatinine kinetics under-
156 estimated lean body mass compared to bioimpedance, with the mean bias being
157 greater for male compared to female PD patients, leading to reporting a much
158 higher prevalence of muscle wasting using creatinine kinetics compared to
159 bioimpedance. Our study using bioimpedance supports previous studies which
160 compared lean body mass estimated by creatinine kinetics with that using
161 isotopic potassium [5]. We noted that there were wide limits of agreement

162 between methods for individual patients, which may relate to variation in dietary
163 intakes and body composition.

164 Our study would suggest that creatinine kinetics is a less reliable method
165 of assessing lean body mass in PD patients and leads to an over estimation of the
166 prevalence of muscle wasting.

167 .

168

169

170 The authors have no conflict of interest

171 The data presented in this paper has not been previously published in part or
172 full form

173

174 Acknowledgements: Dr Suree Yoowanukul was awarded an International Society
175 of Nephrology training award.

176 References

- 177 1. Clinical practice guidelines for nutrition in chronic renal failure. K/DOQI,
178 National Kidney Foundation Am J Kidney Dis 2000; 35(6 Suppl 2):S1-140
- 179 2. Keshaviah PR, Nolph KD, Moore HL, Prowant B, Emerson PF, Meyer M, et
180 al. Lean body mass estimation by creatinine kinetics. J Am Soc Nephrol.
181 1994;4(7):1475-85
- 182 3. Kyle UG, Bosaeus I, De Lorenzo AD, Deurenberg P, Elia M, Manuel Gómez
183 J, et al; ESPEN. Bioelectrical impedance analysis-part II: utilization in
184 clinical practice. Clin Nutr. 2004;23(6):1430-53
- 185 4. Fürstenberg A, Davenport A. Assessment of body composition in
186 peritoneal dialysis patients using bioelectrical impedance and dual-energy
187 x-ray absorptiometry. Am J Nephrol. 2011;33(2):150-6
- 188 5. Dombros N, Dratwa M, Feriani M, Gokal R, Heimbürger O, Krediet R, et
189 al; EBPG Expert Group on Peritoneal Dialysis. European best practice
190 guidelines for peritoneal dialysis. 8 Nutrition in peritoneal dialysis.
191 Nephrol Dial Transplant. 2005 ;20 Suppl 9:ix28-ix33
- 192 6. Persaud J, Thomas M, Davenport A. Indirect ion selective electrode
193 methods potentially overestimate peritoneal dialysate sodium losses.
194 Ther Apher Dial. 2014;18(4):321-5
- 195 7. Davenport A. Does peritoneal dialysate affect body composition
196 assessments using multi-frequency bioimpedance in peritoneal dialysis
197 patients? Eur J Clin Nutr. 2013;67(2):223-5

- 198 **8.** Baumgartner RN, Koehler KM, Gallagher D, Romero L, Heymsfield SB,
199 Ross RR, et al. Epidemiology of sarcopenia among the elderly in New
200 Mexico. *Am J Epidemiol.* 1998;147(8):755-63
201 **9.** Fürstenberg A, Davenport A. Comparison of multifrequency bioelectrical
202 impedance analysis and dual-energy X-ray absorptiometry assessments in
203 outpatient haemodialysis patients. *Am J Kidney Dis.* 2010;57(1):123-129
204 **10.** El-Kateb S, Sridharan S, Farrington K, Fan S, Davenport A. A
205 single weekly Kt/Vurea target for peritoneal dialysis patients does not
206 provide an equal dialysis dose for all. *Kidney Int.* 2016 Sep 18. pii: S0085-
207 2538(16)30400-8 PMID: 27653839
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238

239 **Figure 1:** Bland Altman plot comparing lean body mass measured by
240 bioimpedance and creatinine kinetics showing mean bias and 95% limits of
241 agreement.
242

243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272

Table 1. Demographics of peritoneal dialysis patients used for estimation of lean body mass by Creatinine kinetics and Bioimpedance. Peritoneal dialysis modality, peritoneal membrane transport status, and urea dialysis clearance (weekly Kt/Vurea), laboratory tests and multifrequency bioimpedance body composition. Results shown as median (25th, 75th percentile) or number (percentage).

